GBS vaccine Follow-Up study ends early – antibody duration under review
NCT ID NCT06280157
First seen Feb 28, 2026 · Last updated May 16, 2026 · Updated 16 times
Summary
This study followed women who previously received 1, 2, or 3 doses of an experimental Group B Streptococcus (GBS) vaccine. The goal was to see how long protective antibodies last after vaccination. Participants provided yearly blood samples for 2 to 5 years. The study was terminated early, and no new vaccine or treatment was given.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GROUP B STREPTOCOCCUS INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Simbec-Orion Clinical Pharmacology
Merthyr Tydfil, Pentrebach Merthyr Tydfil CF48 4DR, United Kingdom
Conditions
Explore the condition pages connected to this study.